The purpose of this Solicitation for Offers (SFO) is to obtain competitive Offers from qualified pharmaceutical manufacturers who are interested in providing a commitment to enter into contract negotiations that obligate the successful Manufacturer(s) to deliver at least: (a) an unrestricted supply of direct-acting antiviral (DAA) medications each year for the term of the resulting contract (b) at an annual cost not to exceed the Total State Spend on hepatitis C medications in the Medicaid population, estimated to be $30 million dollars, and the Total State Spend on hepatitis C medications in the Corrections population, estimated to be $5 million dollars, for State Fiscal Year 2018; and (c) any additional complementary services that such manufacturer(s) deem necessary and appropriate to promote the strategies of the Hepatitis C Statewide Elimination Program, reproduced below.